Latest News

Monday 18 May 2015: A Live Surgery Case “Blue Light Cystoscopy with Cysview* and resection of bladder tumors”, was presented during the live surgery plenary sessions at the 2015 American Urological Association meeting on 17 May in New Orleans. The ongoing meeting is the largest international Urological meeting in the world.

Oslo, Norway, 6 May 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies, announces its results for first quarter 2015.

Monday 30 March 2015: Medical News Today features article on Hexvix fluorescence-guided bladder resection: Recently published data demonstrate favorable overall survival outcome in bladder cancer patients

Hexvix blue-light flexible cystoscopy allows for better identification and management of recurrent low-grade tumors in the outpatient setting, providing clinical, patient, and economic benefits.

Oslo, Norway, 12 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that a study published in Scandinavian Journal of Urology concludes that fluorescence cystoscopy with Hexvix® and immediate post-transurethral resection of the bladder (TURB) chemoprophylaxis effectively reduced the recurrence risk and the number of follow-up TURB procedures under clinical routine conditions.

Oslo, Norway, 2 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National Institute for Health and Care Excellence (NICE) in the UK has published its first guidelines on bladder cancer, recommending photodynamic diagnosis for improved detection of bladder cancer.(1) NICE makes evidence-based recommendations for healthcare, with the aim of improving treatment and reducing variations in care.

Oslo, Norway, 12 February 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for fourth quarter and full year 2014.

In a retrospective study Hexvix fluorescence–guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light.

Cevira® advances towards Phase 3 for treatment in patients with cervical high-grade lesions (HSIL)

Kjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30.

Review article highlights Cevira® as a promising tissue sparing alternative to observation and surgical procedures in patients with cervical precancerous lesions

US Nurses’ perspectives on successful implementation of blue-light cystoscopy published in the AORN Journal (November 2014)

“Photodynamic Diagnosis of the Urinary Bladder using Flexible Instruments –Ready for the Outpatient Setting?”

Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third quarter and the first nine months 2014.